Background: Lupus Nephritis (LN) is one of the serious manifestations of SLE. Because of its role in the pathogenesis of LN, IL-6 is likely to be a potential marker, whereas for diagnosing kidney involvement at the subclinical stage, microalbuminuria can be examined. Therefore, early detection of kidney damage in SLE is needed to prevent the progression of NL to permanent kidney failure. This study aims to evaluate the relationship between IL-6 levels and microalbuminuria in SLE patients at Sanglah General Hospital Bali.
Methods: This study used a cross-sectional analytic design, carried out in Sanglah General Hospital on SLE patients, conducted in May until July 2019. Blood and urine samples were taken to obtain the data needed to measure the Mex-SLEDAI score. Cytokine evaluation is done by quantitative examination using enzyme-linked immunosorbent assay (ELISA). Chi-square analysis was done using SPSS version 24 for Windows.
Results: The results of the study were 85 subjects with SLE (94.1% women). The median age is 35 years (18-61 years), and the median duration of illness is three years (0.4-18 years). Most of the patients were in inactive clinical condition, 54 patients (63.53%) and laboratory results were still in the normal range. Steroids (94.1%) are the most widely used therapeutic options. Urine IL-6 levels were obtained with a mean of 0.41Â±0.21 pg/ml, while microalbuminuria levels were obtained with a median of 20 (0-100) mg/L. The results of data analysis stated that there was no significant relationship between urine IL-6 levels and microalbuminuria in SLE (p = 0.972).
Conclusion: In this study, there was no significant relationship between urine IL-6 levels and microalbuminuria.